Genmab

GMAB · Nasdaq Copenhagen · DKK

kr 2,343.00+1.12%+kr 26.00

Close · September 30, 2026

Latest news

Major Shareholder Announcement (opens in a new tab)
GlobeNewswire · Oct 2, 2026
Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4 (opens in a new tab)
Sep 27, 2026
Grant of Restricted Stock Units and Warrants to Employees in Genmab (opens in a new tab)
Sep 24, 2026
Genmab (CPSE:GMAB) Stock Sees Modest Fair Value Cut As Analysts Weigh Pipeline Risks (opens in a new tab)
Sep 24, 2026
Notice to Convene an Extraordinary General Meeting of Genmab A/S (opens in a new tab)
Sep 8, 2026
Could Genmab (GMAB) Stock Win as Royalty Growth Fuels a New Earnings Cycle? (opens in a new tab)
Aug 26, 2026
Genmab to Participate in Upcoming Investor Conferences (opens in a new tab)
Aug 25, 2026
Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab? (opens in a new tab)
Aug 13, 2026
Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More (opens in a new tab)
Aug 12, 2026
Genmab Stock Rises 4.4% as Drug Royalties Lift Outlook (opens in a new tab)
Aug 7, 2026
Genmab (GMAB) Q2 2026 Earnings Call Transcript (opens in a new tab)
Aug 7, 2026
Genmab AS (GMAB) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ... (opens in a new tab)
Aug 6, 2026
Genmab A/S Q2 Earnings Call Highlights (opens in a new tab)
Aug 6, 2026
Genmab shares jump 8% after upbeat results prompt 2026 outlook raise (opens in a new tab)
Aug 6, 2026
Genmab Announces Financial Results for the First Half of 2026 (opens in a new tab)
Aug 6, 2026
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight (opens in a new tab)
Jul 13, 2026
Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results? (opens in a new tab)
Insider Monkey · Jul 8, 2026
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma (opens in a new tab)
GlobeNewswire · Jul 6, 2026
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival (opens in a new tab)
Business Wire · Jun 29, 2026
Capital Increase in Genmab as a Result of Employee Warrant Exercise (opens in a new tab)
GlobeNewswire · Jun 16, 2026
Genmab’s EPCORE Data Deepens Lymphoma Profile As Investors Weigh Upside (opens in a new tab)
Simply Wall St. · Jun 15, 2026
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (opens in a new tab)
GlobeNewswire · Jun 13, 2026
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients (opens in a new tab)
Business Wire · Jun 11, 2026
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients (opens in a new tab)
GlobeNewswire · Jun 11, 2026